2011/04/12 by Karen Curtin, Martha L. Slattery, Wade S. Samowitz · 7 citations
Biochemistry, Genetics and Molecular Biology · #Epigenetics and DNA Methylation #RNA modifications and cancer #Cancer-related gene regulation
paper · pdf · doi:10.4061/2011/902674
openalex publication_date 2011/04/12 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/01
The concept of a CpG island methylator phenotype, or CIMP, quickly became the focus of several colorectal cancer studies describing its clinical and pathological features after its introduction in 1999 by Toyota and colleagues. Further characterization of CIMP in tumors lead to widespread acceptance of the concept, as expressed by Shen and Issa in their 2005 editorial, "CIMP, at last." Since that time, extensive research efforts have brought great insights into the epidemiology and prognosis of CIMP+ tumors and other epigenetic mechanisms underlying tumorigenesis. With the advances in technology and subsequent cataloging of the human methylome in cancer and normal tissue, new directions in research to understand CIMP and its role in complex biological systems yield hope for future epigenetically based diagnostics and treatments.